OPTN vs. CNTX, AMLX, KPTI, PDSB, NVCT, RNAC, VTGN, DMAC, COYA, and MCRB
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include Context Therapeutics (CNTX), Amylyx Pharmaceuticals (AMLX), Karyopharm Therapeutics (KPTI), PDS Biotechnology (PDSB), Nuvectis Pharma (NVCT), Cartesian Therapeutics (RNAC), Vistagen Therapeutics (VTGN), DiaMedica Therapeutics (DMAC), Coya Therapeutics (COYA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Context Therapeutics (NASDAQ:CNTX) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
Context Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 200.00%. OptiNose has a consensus price target of $3.67, indicating a potential upside of 191.01%. Given OptiNose's higher probable upside, analysts plainly believe Context Therapeutics is more favorable than OptiNose.
Context Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500.
Context Therapeutics has a net margin of 0.00% compared to Context Therapeutics' net margin of -41.55%. Context Therapeutics' return on equity of 0.00% beat OptiNose's return on equity.
14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 6.7% of Context Therapeutics shares are owned by insiders. Comparatively, 2.2% of OptiNose shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
OptiNose received 231 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Context Therapeutics an outperform vote while only 63.31% of users gave OptiNose an outperform vote.
Context Therapeutics has higher earnings, but lower revenue than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, OptiNose had 12 more articles in the media than Context Therapeutics. MarketBeat recorded 21 mentions for OptiNose and 9 mentions for Context Therapeutics. OptiNose's average media sentiment score of 0.41 beat Context Therapeutics' score of 0.17 indicating that Context Therapeutics is being referred to more favorably in the media.
Summary
Context Therapeutics beats OptiNose on 9 of the 16 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
